Key Dates Include: Pre-release: December 4, 2024 Open for proposal submissions: January 8, 2025 DSIP Topic Q&A Closure: January 22, 2025, at 10:00 AM MT Close for proposal submissions: February 5, 2025, at 10:00 AM MT Participating DoD Components: Department of the Navy (Navy) Department of the Air Force (Air Force) Defense Health Agency (DHA) Missile Defense Agency (MDA) For further details on active topics and the submission process, you can explore the DoDs SBIR/STTR portal here
Semaglutide combined with cagrilintide (1.2 mg and 2.4 mg) resulted in significantly greater weight loss (15.7% and 17.1%, respectively) at week 20 compared to semaglutide combined with placebo (9.8%) [123]
doi: 10.3390/IJMS25136945 94
Anyone can administer a B12 injection
Phase 3 REDEFINE program ongoing
The regulation of cellular metabolism by tumor suppressor p53